How do you pay?

How to pay the least

Ask for the cash price

Generic carboplatin

No pharmacy we check posts a price for it.

What to do

  1. Ask your pharmacy for the cash price of generic carboplatin.Find pharmacies near you 
  2. Ask one or two other pharmacies too. Cash prices for the same generic can differ a lot from store to store.

A regular generic has the same active ingredient as Paraplatin, and the FDA requires it to work the same way.

Compare every option

Brand name

Paraplatin itself isn’t sold as a prescription anymore.

Not soldNo longer sold

Authorized generic

One was sold before, but not anymore.

Not soldNo longer sold

Regular generic

Same active ingredient as Paraplatin. Fillers and dyes can differ.

Cash priceAsk the pharmacy
Who makes it

Who makes it

6 companies sell a generic of Paraplatin that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.

It’s mostly filled by specialty pharmacies. Your prescriber’s office or insurer can tell you which one to use.

  • Apotex10 mg/mL

    Made by Teyro Labs · Being phased out; sold until November 2027

    How it looks, what’s in it, NDCs

    10 mg/mL

    PackageNDC
    Carton of 5 mL60505-6282-1
    Carton of 15 mL60505-6282-3
    Carton of 45 mL60505-6282-6
    Carton of 60 mL60505-6282-7

    Inactive ingredients: water

    FDA label

  • Eugia450 mg/45 mL, 600 mg/60 mL

    Product page on eugiaus.com

    How it looks, what’s in it, NDCs

    450 mg/45 mL

    PackageNDC
    Carton of 45 mL55150-335-01

    450 mg/45 mL

    PackageNDC
    Carton of 45 mL55150-335-00

    600 mg/60 mL

    PackageNDC
    Carton of 60 mL55150-386-00

    600 mg/60 mL

    PackageNDC
    Carton of 60 mL55150-386-01

    Inactive ingredients: mannitol, water

    FDA label

  • Fresenius Kabi10 mg/mL
    Packages and NDCs

    10 mg/mL

    PackageNDC
    Box of 60 mL63323-172-60

    FDA label

  • Hospira10 mg/mL
    How it looks, what’s in it, NDCs

    10 mg/mL

    PackageNDC
    Carton of 15 mL61703-150-05

    10 mg/mL

    PackageNDC
    Carton of 45 mL61703-262-05

    10 mg/mL

    PackageNDC
    Carton of 5 mL61703-339-18
    Carton of 15 mL61703-339-22
    Carton of 45 mL61703-339-50
    Carton of 60 mL61703-339-56

    10 mg/mL

    PackageNDC
    Carton of 60 mL61703-600-05

    Inactive ingredients: water

    FDA label

  • Natco Pharma50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL, 600 mg/60 mL

    Made by Teyro Labs

    How it looks, what’s in it, NDCs

    50 mg/5 mL

    PackageNDC
    Carton of 5 mL69339-364-05

    150 mg/15 mL

    PackageNDC
    Carton of 15 mL69339-365-15

    450 mg/45 mL

    PackageNDC
    Carton of 45 mL69339-366-45

    600 mg/60 mL

    PackageNDC
    Carton of 60 mL69339-367-60

    Inactive ingredients: water

    FDA label

  • Teva Parenteral Medicines10 mg/mL

    Made by Pharmachemie

    Product page on tevausa.com

    How it looks, what’s in it, NDCs

    10 mg/mL

    PackageNDC
    Carton of 60 mL0703-4239-01

    10 mg/mL

    PackageNDC
    Carton of 60 mL0703-4239-81

    10 mg/mL

    PackageNDC
    Carton of 5 mL0703-4244-01

    10 mg/mL

    PackageNDC
    Carton of 5 mL0703-4244-81

    10 mg/mL

    PackageNDC
    Carton of 15 mL0703-4246-01

    10 mg/mL

    PackageNDC
    Carton of 15 mL0703-4246-81

    10 mg/mL

    PackageNDC
    Carton of 45 mL0703-4248-81

    10 mg/mL

    PackageNDC
    Carton of 45 mL0703-4248-01

    Inactive ingredients: mannitol, water

    FDA label

Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.

What it’s used for

What the FDA label says

Initial Treatment of Advanced Ovarian Carcinoma

Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ).

There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.

Secondary Treatment of Advanced Ovarian Carcinoma

Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.

Source: the FDA label for Carboplatin (Teva Parenteral Medicines, Inc.), August 30, 2022. Full label on DailyMed